News Release

Cleanascite™ Employed To Investigate Lipid Pathway Influences on Hepatocellular Carcinoma

MONMOUTH JUNCTION, NJ , May 11, 2023 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid binding technology to determine the influence of lipid LTB4R2 ligands within pathways associated with Hepatocellular carcinoma.

Sinha, S., Aizawa, S., Nakano, Y. et al. Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 - β-catenin cascade to promote liver tumorigenesis. Nat Commun 14, 2651 (2023). https://doi.org/10.1038/s41467-023-38406-8

Hepatocellular carcinoma (HCC) is the 3 ^rd most deadly malignancy. Activated hepatic stellate cells (aHSC) give rise to cancer-associated fibroblasts in HCC and are considered a potential therapeutic target. In this report, selective ablation of stearoyl CoA desaturase-2 ( Scd2) in aHSC globally suppresses nuclear CTNNB1 and YAP1 in tumors and tumor microenvironment and prevents liver tumorigenesis in male mice. aHSC release 12-hydroxyheptadecatrienoic acid (12-HHTrE) in a manner dependent on SCD and CYP1B1 and their conditioned medium reproduces the LTB4R2-mediated tumor-promoting effects of 12-HHTrE in HCC cells. The article states “Lipid removal from the <10 kDa filtrate with the lipid adsorption reagent (Cleanascite ^TM) abolished the TEAD promoter stimulatory activity (Supplementary Figure), suggesting lipid leukotriene B4 receptor 2 (LTB4R2) ligands are released stearoyl CoA desaturase (SCD)-dependently by activated hepatic stellate cells (aHSC) to activate LRB4R2-YAP1 pathway in Hepatocellular carcinoma (HCC) cells. ” Collectively, the findings suggest aHSC-initiated 12-HHTrE-LTB4R2-CTNNB1-YAP1 pathway as a potential HCC therapeutic target. 

“ This is another example of many studies, whereby Cleanascite™ was used in evaluating the removal of fatty acids for in vitro cancer models. These references show that Cleanascite™ can help identify a characteristic feature of cell response related to lipid removal. Unlike alternative lipid-removal methods that either use solvents, or bind non-specifically to important growth factors, Cleanascite™ is an aqueous suspension product with excellent selectivity for lipids, and so post-treatment, it seamlessly integrates with cellular models of disease. This ultimately helps with investigations such as this, that need to determine whether or not lipids, or factors associated with lipids, impart phenotypic changes to cells.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Link to view our case study, Lipid Removal for Phenotypic Cell Response in Cancer Research (biotechsupportgroup.com)

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords: Hepatocellular carcinoma , long-chain fatty acids, 12-hydroxyheptadecatrienoic acid, lipid removal, activated hepatic stellate cells , leukotriene B4 receptor 2 ligands , Cleanascite™

For Business Development , contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com